In this regard Novo Nordisk is leading the way. We've become increasingly committed to chronic conditions that include cardiovascular disease and chronic kidney disease – the reason being ...

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...

Novo Nordisk has benefited from favorable regulatory decisions, including the recent FDA approval of Ozempic for chronic kidney disease (CKD) patients with type 2 diabetes. This expanded ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial. The Danish ...

Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.

While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...

As the global demand for obesity treatments skyrockets, Vikrant Shrotriya discusses the complex nature of obesity, the ...

The impact of chronic kidney disease (CKD) keeps escalating around the world, and this burden is projected to rise with ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

An Australian medical technology company, Proteomics International, has published a study demonstrating a new blood test ...